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Chronic obstructive pulmonary disease (COPD) is a major public health concern, 
accounting for 3 million deaths annually, 90% of which occur in low- and middle-
income countries. Pulmonary tuberculosis (TB) as a cause of COPD is debated, 





To systematically review evidence for the association between pulmonary 




We performed a systematic review of original English language, peer-reviewed 
literature using the PUBMED/MEDLINE database. Chronic Airflow Obstruction was 
defined on spirometric data (FEV1: FVC Ratio < 0.70; or FEV1: FVC Ratio < lower 




Only 15 studies met eligibility criteria (1 case series, 2 case-control studies, 3 
cohort studies, 6 single-centre cross-sectional studies and 3 multi-centre cross-
sectional studies). All studies except 2, showed evidence of a positiven association 
between pulmonary tuberculosis and chronic airflow obstruction. Four large 
population based surveys were included (n = 4291 to 8066). Three of these 
showed a significant association between TB and Chronic Airflow Obstruction (OR 
1.37 – 2.94), with o ly the BOLD Study failing to demonstrate an association. We 





Our systematic review of the peer-reviewed literature shows evidence for an 
association between a past history of tuberculosis and the presence of COPD. 






















Systematic review of the association between pulmonary tuberculosis and the 




Chronic obstructive pulmonary disease (COPD) is estimated to affect 64 
million people worldwide in 2004. The Global Initiative for Obstructive Lung 
Diseases defines COPD (1) as a preventable and treatable disease, which is 
characterized by airflow limitation that is not fully reversible. The airflow 
limitation is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles or gases (2). COPD is 
a major public health concern, with approximately 3 million people worldwide 
dying of the condition annually. It is estimated that 90% of these deaths arise 
in low- and middle-income countries.(1) Further, COPD is projected to 
become the 3th leading cause of death worldwide by 2030.  
 
The major risk factors for the development of COPD have long been 
considered to be smoking and air pollution from the burning of wood and other 
biomass fuels. (2) However, there is growing interest in additional risk factors 
for the development of COPD. Pulmonary tuberculosis is increasingly being 
recognised as a risk factor in high prevalence countries (4), and recent cross-
sectional surveys performed in low and middle-income countries have 
highlighted this relationship.  
The burden of pulmonary tuberculosis is particularly high in low- and middle-
income countries.  In 2009, there were 9.4 million new cases of TB worldwide 
with 1.7 million deaths. In South Africa, during the same period, the WHO 
estimated 490 000 new cases of tuberculosis, which ranks third only behind 
China and India with their very much larger populations.(5). 
 
To date there have been limited analyses of the magnitude of the contribution 
of TB to the worldwide increasing prevalence of COPD. However, given the 
high prevalence of TB in some regions, this is likely to be high. This is a public 
health issue of potentially great significance.  
 
I propose to perform a systematic review of publications on the association 
between COPD and tuberculosis, and the potential causative role of 
tuberculosis with due consideration of the potential of confounding presented 




To review evidence for the association between pulmonary tuberculosis and 

















This will be a systematic review involving a systematic search of the PUBMED 
/ MEDLINE database.  Additional hand searching will be performed, of 
references in major reviews and other publications. 
 
The PUBMED search will be made using the following search terms for 
Chronic Airflow Obstruction:   
 
Lung Diseases, Obstructive  [MeSH Major Topic] 
Airway Obstruction    [MeSH Major Topic] 
Airways Obstruction 
Obstructive Airway Disease 




The following search terms will be excluded from the above: 
 
Asthma* (wild card)  only if present in the article title 
 
The PUBMED search will be made using the following search term for 
Tuberculosis: 
 
Tubercul*  (wild card)  only if present in the article title or abstract 
 
The PUBMED search will be limited to: 
 
Articles in English  
Adult subjects (older than 19years) 
Human subjects  
 
The search results will be subjected to the following steps: 
1. Papers with titles that do not suggest a link with the research question 
will be eliminated. 
 
2. The abstracts of all remaining papers will be screened for relevance, 
and only those satisfying this requirement will be considered further. 
Where there is no abstract but the paper suggests relevance, the 
publication will be included. 
 
A hand-search will be conducted to ensure that publications that pre-dated 
Pubmed or were not captured in the initial search, will be included. This 
search will involve a   review of references of seminal papers on the 
association of tuberculosis and COPD. Titles and abstracts relevant to the 
















v. Eligibility Criteria for Study Inclusion 
 
The review will include original research into the association between TB and 
COPD. It is predicted that the majority papers will be observational in nature; 
cross-sectional, cohort and case-control studies. Case series will also be 
considered. 
 




vi. Conduct of the Systematic Review. 
 
 A data extraction form containing all relevant fields will be created to ensure 
that all potentially relevant data is recorded from the papers reviewed.  
 
The following will be evaluated and recorded on each paper 
 
a. General aspects: 
 
i. Study design 
 
b. Selection Bias 
 
i. Study Population and setting 
ii. Selection of participants and controls (if appropriate) 
iii. Nature and number of exclusions 
iv. Nature of controls (if appropriate) 
 
c. Measurement Bias 
 
i. Definition and measurement of airflow obstruction 
ii. Definition and diagnosis of “tuberculosis” 
iii. Presence or absence of blinding  (where applicable). 
 
d. Assessment of confounders 
 
Adequately account for the measurement and magnitude of the 
recognised causes of COPD, especially  
i. Smoking (cigarette, cannabis, pipe-tobacco etc) 
ii. Biomass fuel 
 
e. Statistical analysis 
 
i. Techniques of data analysis 

















vii. Research Ethic Committee approval 
 
This dissertation is a systematic review, involving analysis of data in the public 
domain. There will be no patient contact, and no new data will be generated. 





The findings of the systematic review will form the basis of a paper of between 
3000 and 4000 words to be submitted for publication in an appropriate peer 
reviewed journal, and will be submitted as a dissertation, forming part of the 
requirements for a Masters in Public Health degree through the School of 
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Chronic Obstructive Pulmonary Disease (COPD) is estimated to affect 80 
million people worldwide. It is currently the fifth leading cause of death, 
accounting for approximately 3 million deaths annually. Ninety percent of 
these deaths are in low- and middle-income countries. COPD is projected to 
become the third leading cause of death by 2030, with a 30% increase in total 
death rate in the next 10 years. (1) 
 
The traditional risk factors for COPD are a cigarette smoking, exposure to 
dust and biomass fuel, as well as childhood respiratory illnesses. More 
recently, tuberculosis has been identified as a cause of COPD. 
 
Tuberculosis is a major cause of mortality worldwide and results in 
approximately 1.7 million deaths annually. In 2009, there were 9.4 million new 
cases of tuberculosis globally, affecting predominantly low- and middle-
income countries.(2) Many tuberculosis survivors have chronically damaged 
or destroyed lungs, and others have minimal long-term sequelae.  
 
The nature of the relationship between tuberculosis and the subsequent 
development of chronic airflow obstruction has not been well defined. If there 
is an association, the potential impact of tuberculosis on the global prevalence 
of COPD could be large. In addition, there is increasing awareness of the 
heterogeneity of conditions that have been labelled as COPD.  A significant 
proportion of COPD cases have never smoked, representing from 25% to 
45% in different surveys (3), and it is often unclear what aetiological factors 
apply in these cases.  Non-smoking risk factors appear to be especially 
important in developing countries, and it is likely that tuberculosis accounts for 
a significant number of these cases. The existence of tuberculosis-associated 
COPD is debated, as well as how the pathophysiology and response to 
treatment compare with smoking related COPD. 
 
The aim of this study is to systematically review peer-reviewed literature on 
the presence and magnitude of the association between pulmonary 






We made a systematic search of the PUBMED/MEDLINE database and used 
the following search strategy: 
 
A search was conducted for Chronic Airflow Obstruction, the following search 
terms being used: “Lung Diseases, Obstructive [MeSH Major Topic]” OR 
“Airway Obstruction [MeSH Major Topic]” OR “Airways Obstruction” OR 
“Obstructive Airway Disease” OR “Obstructive Airways Disease” OR 















We excluded “Asthma*” (wild card) only if present in the title, in order to limit 
our search to irreversible airflow obstruction. 
 
We then added a search for Tuberculosis using the term: “AND Tubercul*” 
(wild card), only if present in title or abstract. 
 
Articles were limited to the English language, and human, adult subjects 
(older than 19 years). 
 
Papers with titles that did not suggest a link with the research question were 
eliminated. The abstracts of all remaining papers were screened for 
relevance, and only those satisfying this requirement were considered further.   
 
An additional hand search was performed of references contained in seminal 
papers and publications to find reference to papers that pre-dated PUBMED, 
or were not captured in the initial search strategy.  
 
All remaining papers were assessed for eligibility and inclusion in the 
systematic review. Papers were excluded if they did not contain original 
research (e.g. review articles) or had insufficient detail of either methodology 
or results to assess the validity of findings. Additionally, articles were excluded 
if they evaluated patients while on treatment for active tuberculosis, without 
post-treatment follow-up. Where there was doubt about whether an article 
should be included, the article was discussed and consensus was reached 
among the authors. 
 
A flexible definition of Chronic Airflow Obstruction was used for papers dated 
before 1975. This was due to the changing definitions of airflow obstruction 
prior to this date.  However, later articles were excluded if they used non-
standard definitions of airflow obstruction (e.g. FEV1 only; or FEV1: FVC Ratio 
<0.80 rather than 0.70). In keeping with recommendation in current guidelines 
and recent papers, Chronic Airflow Obstruction was defined as FEV1: FVC 
Ratio < 0.70; or FEV1: FVC Ratio < lower limit of normal for age. Use of 
bronchodilators prior to spirometry was noted, however studies without 





The PUBMED/MEDLINE search revealed 419 articles from 1966 until 2011 
that met the initial search criteria. On review of their titles, 44 of these articles 
appeared relevant to the research question, but after review of their abstracts, 
a further 15 were excluded. Of the remaining 29 articles, 10 met inclusion 
criteria. A hand search identified an additional 20 potential articles, dating 
from 1955 until 2011. However, only 5 of these met eligibility criteria, and 















Reasons for exclusion after abstract review, were: Review article (5); only 
active tuberculosis assessed (9); Insufficient information provided to assess 
association (7); Non-standard measures of obstruction used e.g. only FEV1 
(8); Letter to editor (2); Case report (1); Study not relevant to research 
question (2). (See Appendix C) 
 
The fifteen studies included, originated from 25 countries, and included 1 case 
series, 2 case-control studies, 3 cohort studies, 6 single-centre cross-
sectional studies and 3 multi-centre cross-sectional studies. Study size varied 
from 43 to 8,066 subjects. Of these studies, four were population based, four 
were in outpatient or primary care-settings, six were conducted in a hospital 
setting, and one was conducted in retrenched mine workers. Publication dates 
ranged from 1971 to 2011, with the majority published after 2000. 
 
 
There was marked heterogeneity among the included studies, both in terms of 
study design and patient population, making meta-analysis inappropriate. The 
findings are presented below by study type, and table 1 provides a summary 
of the included studies. 
 
Case Series 
In the Case Series of 47 patients, Baig et al (4) showed the prevalence of 
obstruction to be 55.3% with mixed restriction/obstruction in an additional 
14.8%. However this was a highly selected population, selected on the basis 
of having dyspnoea, previous tuberculosis and residual Chest X-Ray (CXR) 
changes of tuberculosis. They were all never-smokers, without a history of 
recognised occupational exposure. 
 
 Case Control Studies 
The two case control studies included in the analysis showed discrepant 
results.  
In a cohort of 289 patients with previous pulmonary tuberculosis from 
Hong Kong and 289 matched controls, Chang-Yeung et al, found no 
association between chronic airflow obstruction and previous tuberculosis on 
multivariate analysis.(5) In this series, previous tuberculosis status was 
defined by a positive response (self-reported) to questions about previous 
tuberculosis on questionnaire. The background prevalence of tuberculosis in 
the community was not reported. By contrast, Pasipanodya et al (U.S.A.) 
found obstruction in 15% of cases (compared with 3% in controls) and mixed 
obstruction/restriction in 13% (compared with 1% in controls).(6) All cases in 
this study had been TB culture positive and completed at least 20 weeks of 
treatment, while controls were adults with latent tuberculosis infection 
presenting for assessment. In both studies smoking status was measured and 
included in multivariate analysis. 
 
 Cohort Studies 
All three of the Cohort studies meeting inclusion criteria, showed an 
association between tuberculosis and the development of obstruction.  
Vargha followed up 99 patients from 1958/1959 to 1974 (15 years), 














treated patients (28 of 59) had airflow obstruction. After 15 years 52% (25 of 
48) were found to have airflow obstruction, 34.8% without initial obstruction 
having developed airflow obstruction, while in 12,0% the obstruction had 
resolved. However 18.6% of patients were lost to follow-up in the medically 
treated group, which may have influenced the results. Smoking status was 
measured but not quantified or adjusted for.  
Similarly, in a retrospective cohort, Willcox et al, found obstruction in 
68% of the 71 patients followed up for a mean of 5.6 years.(8) In a subset 
analysis, patients younger than 45 years, were matched with controls, and 
found to have a significantly lower FEV1/FVC ratio and a higher RV/TLC ratio. 
This matched comparison of younger subjects was an attempt to minimise the 
confounding effect of long-term smoking that may occur in older smokers.  
Potential candidates for this study had been successfully treated at a 
tuberculosis clinic, and those responding to a letter of invitation to return to the 
clinic, were included. The selection process may have affected results by 
either over-estimation (“healthy worker effect”) or underestimation of disease 
(sicker patients died, or were unable to participate). 
In agreement with these studies, Plit et al conducted a prospective 
cohort study of hospitalised patients during their first episode of tuberculosis. 
(9) They found airflow obstruction in 28% of patients (21 of 74), after 
completion of 6 months of TB therapy. Of these, 62% (13 of 21) did not have 
airflow obstruction on commencement of treatment. 
None of the three cohort studies reported whether values for lung 
function were pre- or post-bronchodilator. If pre-bronchodilator, the results 
might have overestimated airflow obstruction. Small improvements in FEV1 
might have resulted in fewer with obstruction (i.e. lower FEV1: FVC ratio), and 
others with reversible airflow obstruction (including any with asthma) would be 
considered as COPD. 
 
Cross-sectional Studies – single institution  
Four of five cross-sectional surveys were hospital based and showed a high 
prevalence of airflow obstruction. The patient populations however, varied 
markedly between the studies, ranging from subjects treated as inpatients, to 
patients referred as outpatients to specialist centres, to patients selected 
retrospectively based on hospital tuberculosis culture results. This 
heterogeneity again prohibited summation of effects observed in the studies. 
Between 1964 – 1966, Snider et al, assessed 1403 patients at medical 
discharge from a tuberculosis sanatorium. He found a reduced FEV1: FVC 
ratio in 42% of patients (23% with obstruction, and 19% with mixed 
obstruction/restriction). Obstruction was associated with age, severity of 
tuberculosis on CXR, and heavier smoking. In this population, only 16.9% 
were non-smokers, and prevalence of airflow obstruction within the subgroups 
tended to correspond with the prevalence of smoking. (10) 
Some 40 years later, Ramos et al (2006) published a cross-sectional 
study of 50 patients attending a tertiary referral clinic, whom had completed 
TB treatment. Patients with other respiratory condition were excluded from the 
analysis. Although 54% were never-smokers, they found airflow obstruction in 
24% of subjects, with mixed obstruction/restriction in a further 34%. The 














referred cases (referral bias), and the large number of exclusions (58%), 
primarily due to co-morbidity and lack of lung function testing. (11) 
Gothi et al also published a prospective cross-sectional study from a 
tertiary referral centre. They investigated 268 consecutive patients referred 
with airflow obstruction, lung function testing and radiology. Thirty six (13.4%) 
patients were considered to have obliterative bronchiolitis. Obliterative 
bronchiolitis was defined clinically (using Turton’s criteria) as i) irreversible 
airflow obstruction ii) reduced FEV1 iii) exclusion of another cause of airflow 
obstruction (e.g. asthma, emphysema, bronchiectasis). The diagnosis was 
confirmed by finding expiratory mosaic attenuation on HRCT scan. They 
attributed the obliterative bronchiolitis to past tuberculosis in 77.8% (n=28) of 
these cases. (12) 
Chung et al ref, also in a tertiary referral hospital setting, reported an 
even higher association between tuberculosis and airflow limitation than in the 
above studies. They retrospectively examined the case notes of all patients 
who had had positive TB cultures and had completed treatment for 
tuberculosis at their institution. Only 7.6% (213 of 2789) of culture positive 
patients had had lung function test. Patients with co-morbid lung disease were 
excluded, leaving 115 subjects (162 lung function tests). Of these 48.6% had 
obstruction, and 9.3% had mixed obstruction/restriction. Again in this study, 
the process of case selection may have overestimated the effect.(13) 
 
In a non-hospital based study, Girdler-Brown et al studied 610 
retrenched Basotho Gold miners. They found a high prevalence of COPD 
despite a relatively young population group with a light smoking history. The 
prevalence of airflow obstruction was 13.5%, in a population of men with an 
average age of 49 years. Among current smokers (34.8%), the median 
smoking history was only 4 cigarettes/day. Among the patients with COPD a 
large proportion had a history of previous tuberculosis (45%).  However, the 
high overall prevalence of silicosis (24.6%) makes it difficult to isolate the 
association between tuberculosis and airflow obstruction, as multivariate 
analysis was not performed.(14) 
 
 Cross-sectional Studies – population based  
Four cross-sectional studies examined the association between tuberculosis 
and chronic airflow obstruction in the general population, providing the most 
generalizable assessment of the association.  
In the largest study of 8,066 subjects, Lam et al used chest 
radiographs with changes attributable to previous tuberculosis to estimate the 
risk of airflow obstruction after tuberculosis infection. They found an odds ratio 
of 1.37 (95% C.I., 1.13 – 1.67). This association remained after adjusting for 
age, sex, smoking, passive smoking, biomass fuel and dust. The study was 
conducted in a high tuberculosis setting, with a prevalence of past 
tuberculosis (on CXR) of 24.2%. However only pre-bronchodilator lung 
functions were performed.(15) 
The multi-centre PLATINO (Proyeto Latinamericano de Investigacion 
en Obstruccion Pulmonar)(16) and PREPOCOL (Prevalencia de EPOC en 
Colombia) (17) cross-sectional studies performed in Latin America also found 
an association between previous tuberculosis and chronic airflow obstruction. 














assessed tuberculosis status by means of a questionnaire. Lung function tests 
were performed after bronchodilators.  
The PLATINO Study was conducted in five Latin American countries 
with 5571 subjects, and estimated the adjusted odds ratio of association to be 
2.33 (95% C.I., 1.50 – 3.62), with the association being stronger in men. The 
prevalence of reported previous tuberculosis was 2.4%. The PREPOCOL 
Study was conducted in five Colombian cities, with 5539 subjects. They found 
an adjusted odds ratio of 2.94 (95% C.I., 1.58 – 5.49), with 25.8% of people 
with a history of tuberculosis having obstruction. This association was greater 
than the association with obstruction for either smoking (OR 2.56; 95% C.I., 
1.89-3.46) or wood smoke exposure (OR 1.50; 95% C.I., 1.22–1.86). The 
prevalence of a previous history of tuberculosis was 1.3% in this population, 
while 30% of all subjects with chronic airflow obstruction had never smoked. 
In contrast, to these three population-based cross-sectional studies, 
the BOLD (Burden of Obstructive Lung Disease) investigators found no 
association between airflow obstruction and a previous history of tuberculosis. 
(18) This study involved 14 countries, and in order to assess non-smoking risk 
factors for obstructive lung disease, they assessed all 4,291 never smokers, 
from their original sample population of 10,000 subjects (42.9%). On 
multivariate analysis the association for women, was OR 1.47 (95% C.I., 0.69-
3.12; p=0.323) and for men was OR 1.65 (95% C.I., 0.43-6.34).  The 
prevalence of previous tuberculosis in this never-smoking population was 
3.2%.  
All three of these multi-centre studies adjusted for biomass (or wood) 
fuel exposure and smoking (BOLD by exclusion of ever smokers), while the 






This systematic review of the literature shows evidence of an association 
between the presence of chronic airflow obstruction on pulmonary function 
testing, and a previous history of tuberculosis. From the literature available, it 
appears that tuberculosis is likely to be causal. However, the lack of 
population based cohort studies prevents definite conclusions in this regard. 
The argument for causation can be strengthened by considering the temporal 
nature of the association, confounders and plausible mechanisms of disease.   
 
 Consistency of Evidence for Association 
 
The strongest body of evidence comes from three large population-based, 
cross-sectional studies that showed a statistically significant association 
between previous tuberculosis and COPD. The PLATINO Study (n=5571) 
showed an adjusted odds ratio of 2.33 (95% CI: 1.50 – 3.62)(16), the 
PREPOCOL Study (n=5539) an adjusted odds ratio of 2.94 (95% CI: 1.58-
5.49)(17), and Lam et al (n=8066) estimated an adjusted odds ratio of 1.37 
(95% CI: 1.13-1.67)(15). The PREPOCOL study showed the association 














cigarette smoking or wood smoke exposure. Additionally, the PLATINO Study 
found that a history of tuberculosis was associated with more severe grades 
of obstruction. These findings are supported by the other smaller cross-
sectional, cohort and case-control studies. 
 In contrast to these studies, the BOLD investigators were unable to find 
an association between the presence of COPD and a history of tuberculosis, 
even when they assessed airflow obstruction in never-smokers (n=4291). 
(19)(18) However, the median prevalence for tuberculosis (using 2009 
figures) among the fourteen countries participating in the BOLD Study was 
only 10.45 / 100,000 population (range: 2.4 – 782 / 100,000), compared to the 
global prevalence of 201/100,000 during the same time period. (20) In this 
study, only 2 countries had a prevalence of tuberculosis that was higher than 
the global average. Thus the BOLD study was predominantly performed in 
countries with a low burden of tuberculosis. By averaging the odds ratios 
between sites, the combined measure of association is likely to tend towards 
the null, thereby underestimating the association. This could have resulted in 
the dilution of effects from the high prevalence sites. For example, in the 
South African arm of the study (the site with the highest prevalence of both 
tuberculosis and COPD), Jithoo et al found a strong association between 
chronic airflow obstruction and a history of previous tuberculosis. For people 
with mild COPD (GOLD Stage I/II), the odds ratio was 2.6 (95% CI: 1.5-4.6). 
The association was even stronger for people with GOLD Stage III/IV disease. 
(OR 8.9; 95% CI: 4.2-18.9) (21) (22) 
A further reason for the differences in the associations observed in 
different studies, is the basis on which previous tuberculosis was diagnosed. 
Self-reporting by subjects, using questionnaires may result in an 
underestimation of the burden of disease. This was noted by Lam et al found 
the prevalence of previous tuberculosis to be 2.9% when using 
questionnaires, and 24.2% when assessed using chest x-rays, in the same 
population. (15) These investigators suggest that, in their population, 
stigmatisation might be a reason for the under-reporting on questionnaire. If 
this finding holds true in other population groups, it may cause significant 
underestimation of the burden of COPD associated with tuberculosis by 
questionnaire-based studies. 
 
Eight studies were omitted from this review because of non-standard 
measures of airflow obstruction (e.g. FEV1 only; or FEV1: FVC Ratio <0.80 
rather than 0.70), and could not be used to address the review hypothesis. 
However, the findings within these studies were not inconsistent with the 




Causality cannot be based on cross-sectional studies alone, but is 
strengthened when evidence of a temporal relationship is found between 
pulmonary tuberculosis and the subsequent development of chronic airflow 
obstruction. Relevant questions are whether the obstruction develops during 
active tuberculosis; during treatment; or during the subsequent years as part 















Obstruction during active pulmonary tuberculosis: 
 
Several studies have shown that airflow obstruction occurs in many patients 
during the active phase of tuberculosis. As early as 1955, Anno & 
Tomashefski, showed active tuberculosis to be associated with emphysema in 
their case series (n=25). They defined emphysema as a raised RV/TLC ratio. 
(23) This limitation in airflow has been confirmed in numerous studies, with 
the prevalence of airflow obstruction ranging from 11% - 50.8% (24), (25), 
(26), (27), (28), (29), (30), (9). Additionally the incidence of combined airflow 
obstruction and restriction (defined as a FEV1: FVC ratio <70% and FVC < 
80% predicted) appears high.  
 
Obstruction on completion of treatment: 
 
There is a relative paucity of data on the progression (or resolution) of 
obstruction after completion of medical treatment. Plit et al, studied a 
hospitalised cohort of patients during their first episode of tuberculosis (n=74). 
(9) During the course of treatment, restrictive defects became less prevalent, 
while airflow obstruction developed in some. The prevalence of restriction 
declined from 57% at diagnosis and commencement of treatment, to 24% 
after treatment completion (usually at 6 months). In contrast, airflow 
obstruction increased from 11% (n=8) at diagnosis, to 28% (n=21) on 
treatment completion. Thus 62% of post-treatment airflow obstruction 
developed while on treatment.  
 
Obstruction following successful treatment 
 
Evidence from longer-term follow-up studies after completion of medical 
therapy for tuberculosis is inconclusive regarding the role of pulmonary 
tuberculosis in the pathogenesis of COPD. Vargha followed up 99 patients 
after discharge from hospital.(7) He found high initial rates of airflow 
obstruction (47.5%). After 15 years of follow-up, 34.8% of the medically 
treated patients had developed new airflow obstruction, while in 12,0% the 
airflow limitation had resolved. Unfortunately, in this study, smoking (as a 
confounder) was not adequately adjusted for, limiting the conclusions made.  
In a retrospective review of 115 patients (162 lung function tests) who 
had completed tuberculosis treatment and undergone lung function testing, 
Chung et al found a gradual decline in pulmonary function (both FEV1: FVC 
ratio and FEV1) until about 18months after completion of treatment, with some 
subsequent improvement thereafter. (13) 
Hnizdo et al, in a retrospective review of data from a cohort of 27,660 
gold miners, reported that loss of lung function was highest 6 months after 
tuberculosis diagnosis, and stabilised after 12 months. However, their 
conclusions were based on FEV1 alone rather than on FEV1: FVC ratio, and 
was therefore not able to distinguish between restrictive and obstructive lung 
disease. (31)  
All the above findings, although inconclusive, suggest that the active 
phase of disease associated with the post pneumonic changes may be more 
restrictive in nature or restriction might mask obstruction, the latter appearing 














phase chronic airflow obstruction may appear and/or progress over months, 
or perhaps even years. The deterioration may additionally have two phases, 
with an initial more rapid deterioration, followed by a period of stabilization. 
 
Confounding by smoking 
 
When assigning causality, it is important to consider potential confounders in 
the observed association between tuberculosis and COPD. Cigarette smoking 
undoubtedly has the potential to act as a confounder. Smoking is the major 
risk factor worldwide for the development of COPD. (32) There is also good 
evidence of an association between smoking and tuberculosis, with smokers 
being twice as likely to develop tuberculosis. (33) This association was also 
noted by Lam et al. These investigators found smoking to be more common 
among people with radiological evidence of tuberculosis, compared to those 
with a normal chest X-ray (31.9% vs. 19.7%; p<0.001). (15) 
But smoking alone in insufficient to explain the association between 
tuberculosis and COPD. Vargha noted that 32.5% of patients with airflow 
obstruction after TB treatment were non-smokers. (7) Willcox and Ferguson 
also found evidence of increased airflow obstruction in patients treated for 
tuberculosis, when compared to smoking matched controls. (8) Additionally, 
both the large PLATINO (16) and PREPOCOL studies (17) adjusted for 
smoking (and biomass fuel) and still found a significant association between 
previous tuberculosis and COPD. Lam et al confirmed this association in non-
smokers, (OR 1.30; 95% CI: 1.02-1.66), even though the association was 
noted to be greater in smoking subjects (OR 1.47; 95%CI: 1.04-2.08). (15) 
Smoking therefore, cannot account for the association between 
tuberculosis and COPD on the basis of confounding. However, it is highly 
likely that smoking has an effect-modifying role in tuberculosis patients who 
develop COPD. Although not proven, it is probable that the pathological 
processes that occur during tuberculosis resulting in airflow obstruction are 
compounded and exacerbated by the inflammatory effects of smoking. 
 
Hypotheses of pathogenesis 
 
The mechanism through which tuberculosis causes chronic airflow obstruction 
is largely speculative, and several hypotheses have been previously 
suggested.(10) It is useful to consider these potential mechanisms as either 
involving the bronchial tree, small airways or the lung parenchyma per se.  
 
Hypothesis of bronchial tree involvement 
 
Tuberculosis is well known to involve the bronchial tree. Long et al, using CT 
scanning, found virtually all cases of active tuberculosis (n=25), to have 
endobronchial disease. They defined endobronchial disease as the presence 
of centrilobular nodules, branching linear structures, “tree-in-bud” appearance, 
or poorly defined nodules. (30) This submucosal infection and inflammation of 
the airways in the acute phase, may subsequently progress to peribronchial 















Chronic airflow obstruction following tuberculosis may also result from 
the development of post-tuberculous bronchiectasis. The abnormal, 
permanent dilation of the bronchi that defines bronchiectasis can arise 
through a number of mechanisms. Endobronchial tuberculosis can result in 
damage to the bronchi with subsequent fibrosis and stenosis. This leads to 
distal dilation and bronchiectasis. Enlarged lymph nodes have also been 
implicated as a cause of bronchiectasis, through obstruction and dilation of 
bronchi. Additionally bronchi in areas of parenchymal fibrosis and scarring 
may become distorted and dilated, with resultant bronchiectatic change. (10) 
 
It is also possible that the residual destructive fibro-cavitatory changes 
that are common after tuberculosis, may lead of airflow obstruction per se. 
This has not been well studied, however, Lee et al examined 11 patients with 
extensive residual damage on chest x-ray following tuberculosis, who 
exhibited airflow obstruction. They found high airway resistance, and raised 
residual volumes in these subjects, despite low FVC and FEV1. (34) It is 
possible that the observed traction and distortion, causes increased airway 
resistance or premature closure of the airways during expiration, resulting in 
the observed obstruction. Alternatively, premature airway closure with air 
trapping could be due to loss of elastin in the tissues, with consequent inability 
to maintain airway patency during expiration. Further research is needed to 
confirm and elucidate this theory. 
 
Several authors have tried to correlate the extent of tuberculosis on 
chest x-ray, with lung function test results, in an attempt to link structure to 
function, Their findings show consistent evidence of an inverse relationship 
between extent of disease on initial CXR and FEV1 following 
treatment.(8,9,13,35) However the data relating chest x-ray damage to airflow 
obstruction (i.e. FEV1: FVC ratio) is less convincing. Snider et al, showed an 
association of disease extent with the presence of airflow obstruction (10), 
while Willcox et al, found only a non-significant trend between original chest x-
ray score and the extent of airflow obstruction. (8)  
Furthermore, it appears likely that profusion of disease based on chest 
x-ray alone, does not determine the severity of airflow obstruction. For 
example, Plit et al found, that despite a highly significant radiological 
improvement on treatment for their cohort, 13 of 74 patients developed new 
airflow obstruction.(9) 
 
Hypothesis of small airways disease 
 
Small airways involvement by is another potentially important mechanism 
producing airflow obstruction. Bronchiolitis Obliterans can develop as a result 
of inflammation, fibrosis or distortion, of airways that do not contain cartilage 
(usually <2mm in diameter). In the correct clinical context, and after exclusion 
of other conditions, Bronchiolitis Obliterans can be diagnosed by finding 
airflow obstruction on lung function testing, with suggestive features on 
HRCT. These HRCT features include mosaic attenuation on expiratory scans, 
providing indirect evidence of gas trapping. Both Gothi et al and Long et al 
have showed a strong association with a mosaic pattern on HRCT and 














pattern of attenuation at diagnosis of tuberculosis. These mosaic patterns 
were strongly (but not exclusively) associated with cavitatory disease, and 
persisted despite completion of treatment. Although mosaic attenuation in the 
context of tuberculosis, may be due to vascular injury or hypoxic 
vasoconstriction, it is more likely to be due to gas trapping. This is supported 
by Gothi et al, who found Obliterative Bronchiolitis, defined by mosaic 
attenuation on HRCT, to be the third leading cause of chronic airflow limitation 
after Asthma and COPD (n=268). Seventy-eight percent (77.7%) of these 
cases were associated with previous tuberculosis. 
 
 Hypothesis of Inflammatory Parenchymal Destruction 
 
Another possible mechanism for the observed airflow obstruction is 
development of abnormal, permanent dilation of airspaces distal to the 
terminal bronchioles (emphysema), similar to the damage caused by smoking. 
It is plausible that the inflammatory environment established during acute 
tuberculosis infection may persist after treatment, and result in pathological 
changes similar to that observed in emphysema related to smoking. There is 
evidence of some similarity and overlap in the two disease processes. For 
example, matrix metalloproteinases (MMPs), responsible for digestion of 
collagens and gelatins (specifically, MMP-1 & MMP-9), are raised in both 
tuberculosis and emphysema. (36) 
In smoking related emphysema, the inflammatory milieu and 
progression of emphysema can persist long after the cessation of 
smoking.(37) It is possible, that a similar process is established with 
tuberculosis resulting in ongoing lung destruction long after the acute episode. 
This may, in part, account for observed deterioration of lung function that 
appears after treatment completion.  
What is less clear is to what extent emphysematous changes 
contribute to the observed post-tuberculous airflow obstruction. In 1968, 
Martin et al, performed a small autopsy study of patients who had active 
tuberculosis. (38) Of those where lung function were measured, 65% had 
Diffuse Obstructive Pulmonary Syndrome. He found that, despite high rates of 
abnormal expiratory flow, there was no difference in the type and extent of 
Emphysema, and no difference in measures of Chronic Bronchitis, when 
compared with controls. In this study, controls were only matched by sex, and 
smoking was not measured in either cases or controls. Therefore, the 
contribution of smoking to emphysema in the individual groups of this study 
could not be adequately assessed. Additionally all cases had active 
tuberculosis, making it difficult to draw conclusions about post-tuberculous 
emphysema.  
In emphysema, the diffusion capacity of carbon monoxide (DLCO) is 
frequently reduced, due to loss of alveolar-capillary surface area. However, 
Lee et al found that in a small group of patients with post-tuberculosis airflow 
limitation (n=11), the mean DLCO was not low, suggesting a lack of 
emphysema. (34) 
Because of the paucity of data, and lack of HRCT imaging studies 
assessing emphysema scores, we are unable to exclude emphysema as a 















It is probable that no single mechanism of pathogenesis proposed 
above is solely responsible for the development of post-tuberculous airflow 
obstruction in all patients. But the relative contribution of each disease 
mechanism to disease burden is not known, and further research is 

















There is little data on the physiological response of post-tuberculous airflow 
obstruction to bronchodilators.  Lee et al found bronchodilator response rates 
to be lower in post-tuberculous airflow limitation, compared with COPD 
controls (n=11).(34) While Ramos et al found only 6% (3 of 50) of patients 
had reversibility when given a bronchodilator.(11) These findings need further 
confirmation, and further studies need to be performed to assess possible 
treatment options. 
 
 Limitation of Review 
 
This systematic review has several limitations. Firstly, like all systematic 
reviews, there is the potential for publication bias. Studies showing negative 
findings are more likely not to be published, and therefore affect our findings.  
Secondly, there was marked heterogeneity among the studies found, 
both in terms of study design and subject selection. It was therefore, not 
possible to perform a meta-analysis on these studies, and thus difficult to 
determine the true magnitude of the association. Additionally, it may not be 
advisable to perform a meta-analysis using data from population groups with 
vastly different prevalence rates of tuberculosis. For example, many of the 
large population based studies were performed in developed nations, where 
TB prevalence is low, and smoking common. Therefore it would be difficult to 
study the effect of tuberculosis independent of smoking, and conclusions are 
therefore likely to tend towards the null hypothesis.  
Thirdly, it is not possible to accurately measure the true proportion of 
COPD that is attributable to tuberculosis from the available published 
literature. There is a notable lack of prospective, community based cohort 
studies, needed to assess the lifetime risk of developing COPD after an 
episode of tuberculosis. Many of the studies published were not prospective, 
and were performed on highly selected populations. This may lead to an 
overestimation of the association in these studies.  
Fourthly, as only English language articles were reviewed, it is possible 
that results of studies published in other languages that have bearing on the 
research question were overlooked.  
  
Finally, on the available literature, causality is strongly suggested but 
not definitively proven.  The evidence for causality includes a strong 








Our systematic review of the peer-reviewed literature shows evidence of an 














This association is independent of cigarette smoking and biomass fuel 
exposure. The development of airflow obstruction continues in some subjects 
after treatment completion, with an initial deterioration followed by 
stabilisation. The pathogenesis of the airflow obstruction is unclear, and may 
include structural changes in airways ranging from large airways to 
bronchioles, the latter possibly including obliterative bronchiolitis.  To date, no 
studies have attempted to examine the generation of airways responsible for 
the airflow limitation associated with healed pulmonary tuberculosis.  With 
modern imaging techniques and refined tests for examining small airways 
disease, structure/ function analysis of these patients should be informative 
and cast light upon the pathogenesis of airflow limitation. In addition, there is 
a need for further longitudinal cohort studies in high tuberculosis prevalence 
areas to provide data on changes in lung function from baseline screening 
through an episode of pulmonary tuberculosis, with follow-up continuing for 
years after the event. Longitudinal studies of this nature have commenced in 
patients being treated for HIV infections, but their results will not be 
generalisable to non-HIV infected persons. Questions that remain to be 
answered are whether tuberculosis-associated COPD is progressive and 
deteriorates more rapidly than usual forms, whether tobacco smoking and 
pulmonary tuberculosis are simply additive in causing airflow obstruction, or 
whether there is evidence for a synergistic relationship between these risk 
factors. Finally, whether tuberculosis-associated COPD responds to the 
treatments recommended for the usual form of COPD, or whether other 
approaches must be developed. Further, whether treatments directed at 
limiting airway damage, and particularly endobronchial fibrosis might be 
effective. This might include the use of anti-inflammatory or even anti-fibrotic 
agents. 
The size of the tuberculosis problem worldwide, and particularly in areas 
where tobacco smoking is also increasing, provides conditions for a dramatic 
increase in cases of COPD. Clinical case series attest to the morbidity, 
mortality and burden placed on health services associated with COPD. This 
should spur attempts to better understand and develop effective prevention 

















































          
Baig et al (4) 2010 Pakistan Case-Series 47 Referral Hospital 
Patients referred with 










 55.3% had obstruction 
14.8% mixed 
obstruction/restriction 




          
Chang-Yeung et 
al (5) 
2007 Hong Kong Case-Control 
289 
(cases) 












FEV1: FVC Ratio 
Patient 
questionnaire 




prevalence not stated. 









Culture positive TB 











FEV1: FVC Ratio 
TB culture  
 
Cases: 15% had obstruction, 
13% mixed PFTs 
Controls: 3% had obstruction, 
1% mixed PFTs 
Higher rates of 




          
Vargha (7) 1983 Hungary 
Cohort 
(15 yr follow-up) 
99 Outpatient clinic 
Patients discharged as 
cured in 1958/59 
N Smoking FEV1: FVC Ratio Hospital records 
After 15 years in medically 
treated patients: 
52% had obstruction. 
(34.8% without initial 
obstruction developed new 
obstruction; and 12% with 
initial obstruction normalised 
PFTs) 
Loss to follow-up (in 
medically treated 
patients) was 18% 
Willcox et al (8) 1989 South Africa 
Retrospective cohort 
(Mean follow-up of 5.6 
years) 
71 Primary care clinic 
All patients treated for 












Overall 68% had obstruction. 
Young patients had 
significantly lower FEV1: 
FVC Ratio and higher RV, 
compared with matched 
controls  
Potential bias in 
selection of cohort. 
Plit et al (9) 1998 South Africa 
Prospective cohort 





with first episode TB 
N Smoking, HIV FEV1: FVC Ratio Hospital records 
 
After treatment completion 
28% (n=21) had obstruction. 
Of these 62% (13) were new. 
  
Exclusion of MDR-TB, 
Previous TB and Co-
existing pathology 
 
Cross-Sectional – Single Institution 
 
          






Patients at medical 
discharge  
N Smoking FEV1: FVC Ratio Hospital records 
 
Obstruction in 23%, Mixed 
obstruction/ restriction in 19% 
 
Very high rates of 
smoking (84%) 
Ramos et al (11) 2006 Brazil 
Cross-sectional (single 
centre) 
43 Referral Hospital 
Complex TB cases 
referred, who had PFTs 
N Smoking Not defined Patient records 
24% had obstruction. 34% had 
mixed obstruction/restriction 
 
Severity of PFT 
matched CXR changes. 
Highly selected 
population. (54% never 
smokers) 
 
Chung et al (13) 2011 Taiwan 
Cross-sectional (single 
centre) 
115 University Hospital 
 Patients with positive 
TB cultures, who 
underwent PFTs after 
TB treatment. 
N Smoking FEV1: FVC Ratio TB culture 
 
Obstruction in 48.6%; Mixed 
obstruction/ restriction in 
9.3% 
 
Median follow-up of 16 
months. 
Only 7.6% of culture 
positive TB had PFTs. 
NTMs isolated in 
26.4% of isolates. 
Gothi et al (12) 2007 India 
Cross-sectional (single 
centre) 
268 Referral Centre 
Patients referred for 
investigation of chronic 
airflow-obstruction 
N Smoking 
Post BD FEV1: 
FVC Ratio 
Patient history and 
records 
77.7% of Obliterative 






























FEV1: FVC Ratio 
Patient history 
 
Of patients with COPD, 45% 
had past/current TB 
 
Not corrected for 
smoking, no post BD 
spirometry 
 
Cross-Sectional – Population 
 
          
Lam et al (15) 2010 China 
Cross-sectional (single 
centre) 













OR 1.37 (1.13-1.67) 
Only Pre BD values.  
Large difference 
between self-reported 
previous TB and CXR 
changes of previous TB 
Menezes et al 
(16) 
2007 





5571 Population Multistage sampling N 
Smoking, work dust, 
fossil fuel, childhood 
illness 




OR 2.33 (1.50-3.62) 
132 had past TB 
TB history associated 
with more severe 
COPD.  

















OR 2.94 (1.58 – 5.49) 
72 had past TB 
25.8% of past-TB had 
COPD.  






















Women: OR 1.47 (0.69-3.12) 
 
Men: 
OR 1.65 (0.43-6.34) 
Only “never smokers” 
included.  
Table 1. Studies included in Systematic Review 
Abbreviations: TB – tuberculosis; BD – bronchodilator; CXR – Chest Xray; wks – weeks; PFT – Pulmonary function test; RV – Residual volume; MDR-TB – Multidrug resistant tuberculosis; NTM – Non-
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